Mizoribine

DRUG3 trials

Sponsors

Sanofi, Lee's Pharmaceutical Limited

Conditions

BK VirusKidney Transplant ImmunosuppressionKidney Transplant RecipientsRheumatoid Arthritis

Phase 3

A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)

CompletedNCT02373202

SanofiRheumatoid Arthritis

Start: 2015-02-28End: 2016-11-30Updated: 2018-01-30

Phase 4

An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients

Lee's Pharmaceutical LimitedBK Virus, Kidney Transplant Recipients

Start: 2022-05-01End: 2024-05-01Target: 30Updated: 2022-03-24

Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients

Lee's Pharmaceutical LimitedKidney Transplant Immunosuppression

Start: 2023-01-01End: 2025-03-01Target: 152Updated: 2023-11-02

Related Papers

Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (&lt;65 and ≥65 years): A <i>post hoc</i> analysis of Japanese Phase 3 clinical trials

Modern Rheumatology2024-07-282 citations

The effects of sarilumab as monotherapy and in combination with non-methotrexate disease-modifying anti-rheumatic drugs on unacceptable pain in patients with rheumatoid arthritis: A post-hoc analysis of the HARUKA phase 3 study

Modern Rheumatology2024-07-271 citations

Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA)

Modern Rheumatology2019-07-0328 citations